Lexaria closes registered direct offering and warrant placement for about $3.5 million gross

Lexaria Bioscience Corp. (Nasdaq: LEXX) closed a registered direct offering and a concurrent private placement of warrants on December 16, 2025. The offering raised gross proceeds of approximately $3.5 million before placement agent fees and other expenses, according to a Form 8-K filed December 16, 2025. The sale came from a purchase agreement signed December 14, 2025 with certain institutional investors.

The shares and the warrants

Lexaria sold 2,661,600 shares of common stock at $1.315 per share in the registered direct offering. In the private placement, it issued warrants for up to 2,661,600 shares at an exercise price of $1.19. The shares were sold under a Form S-3 shelf that became effective on January 30, 2025, with a prospectus supplement dated December 14, 2025.

The warrants were not registered. Lexaria sold them under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. They can be exercised on issuance, expire on the fifth anniversary of the effectiveness of the resale registration, and may be exercised without cash in some cases. A holder cannot exercise if that would take its stake above 4.99% of outstanding shares. The holder can raise that limit to no more than 9.99% on 61 days' notice. If the company fails to deliver shares on a valid exercise, it must pay cash as liquidated damages, and the warrants carry buy-in rights.

The company's press release, dated December 15, 2025, described the shares as priced at-the-market under Nasdaq rules.

Who placed the deal

H.C. Wainwright & Co., LLC was the exclusive placement agent. Under an engagement agreement dated August 12, 2025, Lexaria agreed to pay a cash fee of 7.0% of gross proceeds. It also agreed to issue the agent, or its designees, warrants for up to 93,156 shares at $1.6438 per share, equal to 3.5% of the shares sold at closing. Those agent warrants expire five years from the start of sales. Lexaria will also reimburse $20,000 for non-accountable expenses, up to $50,000 of legal costs and $15,950 for clearing fees.

Sichenzia Ross Ference Carmel LLP, securities counsel to the company, gave the opinion on the validity of the shares, filed as Exhibit 5.1. The filing does not name counsel for the placement agent or any other adviser.

Registration and lock-up

Lexaria must file a resale registration statement on Form S-1 or another appropriate form within 15 days of the purchase agreement. It must try to have that statement declared effective within 45 days of closing, or 75 days if the Securities and Exchange Commission conducts a full review. For 30 days, subject to exceptions, the company may not issue more shares, announce an issuance, or file other registration statements, apart from the registrations tied to this deal.

The cash position

The company's annual report on Form 10-K, for the year ended August 31, 2025 and filed November 28, 2025, says its financial statements were prepared on a going-concern basis. Management concluded there is substantial doubt about its ability to continue as a going concern for at least one year after those statements were issued. As of August 31, 2025, Lexaria had unrestricted cash and cash equivalents of approximately $1.8 million, against $1.5 million of current liabilities.

The annual report says future operations depend on raising equity, forming a collaborative or strategic partnership, reducing spending, and eventually generating revenue. It says the company will need more financing even after counting expected inflows from executed license agreements. The company continues to explore equity financing arrangements.

The 8-K gives the use of proceeds as working capital and general corporate purposes. The press release adds research and development efforts. Investors who buy shares in the offering can resell them immediately, but the warrant shares cannot be sold until the resale registration takes effect.

Background

Lexaria describes itself as a biotechnology company that uses its patented DehydraTECH drug delivery technology to improve the bioavailability of active pharmaceutical ingredients. The annual report says the company's business plan includes encouraging industry participants to license the technology. It names GLP-1 and GIP drugs, NSAIDs, nicotine and cannabidiol among the molecules involved.

Chief Executive Officer Richard Christopher signed the 8-K.

Report an error

Companies in this story

LEXXLexaria Bioscience Corp.NASDAQ · CanadaOpen the starter desk